[ad_1]
A decision on this step was previously scheduled to be made on Wednesday.
Under pressure from EU members due to the deteriorating epidemiological situation, the Amsterdam-based European Medicines Agency (EMA) had previously decided to present a decision originally scheduled for January 12.
“Today, Monday, January 4, a meeting of the EEA Committee for Medicinal Products for Human Use (CHMP) will be held to discuss the Moderna vaccine,” the agency said in a statement.
The EEA stated that it would issue an appropriate notice without delay “if the CHMP comes to today’s meeting [bendrą] opinion “.
If the decision is made to allow one year to distribute Moderna vaccine in an emergency, committee members will meet again on Wednesday, the agency added.
As demonstrated by clinical trials with 30.4 thousand. The efficacy of the vaccines in the Modern American company is 94.1% compared to the placebo group.
The modern vaccine would be the second to be licensed in the European Union. On December 21, the EVA authorized the distribution of the COVID-19 vaccine, developed by BioNTech and Pfizer, under an expedited procedure.
However, last week, the EVA said it is unlikely that the coronavirus vaccines developed by the British company AstraZeneca and the University of Oxford, which were approved in the UK last Wednesday, could be distributed in the European Union until next month.
With the approval of two vaccines each by Britain and the United States, the EEA has come under pressure to speed up its procedures. Germany was under special pressure.
European Commission: vaccines will be enough
After strong criticism for the lack of a vaccine, the European Commission defends its acquisition strategy.
“We will have enough vaccine,” Commission spokesman Eric Mamer said in Brussels on Monday. But the vaccine has yet to be manufactured and distributed, he said.
“We condemn this campaign as if it is already over. But the campaign is just beginning,” Mamer said. As early as fall, it was said that the vaccine supply would gradually expand from the end of 2020 and that large shipments could be expected in April.
“So it is quite surprising when we now say, ‘Why are not all doses of the vaccine on the market yet?'” The spokesperson said. This was said to be clear from the start.
The Commission has confirmed this weekend that Biontech and Pfizer are being consulted on additional doses of the vaccine, in addition to the 300 million already ordered. The vaccine from these companies is so far the only one registered in the EU.
[ad_2]
